WODA members (EffRx Pharmaceuticals, Medis, Orpharm, OrphanDC G, and Vector Pharma), are pleased to announce the addition of Decisive Consulting to the Alliance network. With a highly experienced team, Decisive Consulting has capabilities to solve many challenging issues related to pricing, market access, portfolio design and launch strategy.
WODA aims to provide comprehensive support to pharmaceutical and biotech companies working in rare diseases, oncology and highly specialized therapeutics portfolio, starting from named patients programs through to full commercialization.
The access lens of Decisive Consulting will allow the Alliance to integrate vertically by offering existing and future partners a host of expanded services to navigate access, pricing and commercialisation strategies, WODA will help partner companies deliver more innovative treatments to the patients that need them.
The Decisive team has a wealth of experience across multiple therapeutic areas and geographies as well as being a leader in the rare and orphan space,
commented WODA Chairman Patrick Jordan.
Given that we operate primarily in the orphan space dealing with heterogenous, complex markets, the addition of Decisive’s consultancy services and know-how will be a value-add to our partners as well as an upgrade to the Alliance’s scope of services.
In total, WODA covers 68 countries in the following regions: Turkey, Middle East and North Africa; Russia & CIS region; Central and Eastern Europe; Latin America; Switzerland. These regions cover approximately 1.6 billion people. This is very complementary to Decisive’ s commercial strategy and access focused expertise that extends globally, enhanced via the alliance.
We know how complex it is to bringing innovative medicines and technologies to market, in Europe and beyond. Our consultants have years of experience in delivering access, commercialisation and transformation strategies that lead our clients to achieve their commercial aspirations,
said Esther Nzenza, CEO, Decisive Consulting.
By combining our first-hand knowledge and expertise, we thrive on helping companies navigate the complexities of getting to market including access strategies (reimbursement to Named Patient Programmes), policy setting, pricing and launch readiness. We are pleased to offer our partners a more global view by being part of the WODA network, as we all work together to deliver access to life-saving and life altering treatments to patients around the world.
About WODA Founding Members: EffRx Pharmaceuticals, Medis, Orpharm, OrphanDC G, and Vector Pharma.
